The intracellular parasite Toxoplasma gondii enjoys a wide host range and is adept at surviving in both naive and activated macrophages. Previous studies have emphasized the importance of the active serine-threonine protein kinase rhoptry protein 18 (ROP18), which targets immunity-related GTPases (IRGs), in mediating macrophage survival and acute virulence of T. gondii in mice. Here, we demonstrate that ROP18 exists in a complex with the pseudokinases rhoptry proteins 8 and 2 (ROP8/2) and dense granule protein 7 (GRA7). Individual deletion mutant Δgra7 or Δrop18 was partially attenuated for virulence in mice, whereas the combined Δgra7Δrop18 mutant was avirulent, suggesting these proteins act together in the same pathway. The virulence defect of the double mutant was mirrored by increased recruitment of IRGs and clearance of the parasite in IFN-γ-activated macrophages in vitro. GRA7 was shown to recognize a conserved feature of IRGs, binding directly to the active dimer of immunity-related GTPase a6 in a GTP-dependent manner. Binding of GRA7 to immunity-related GTPase a6 led to enhanced polymerization, rapid turnover, and eventual disassembly. Collectively, these studies suggest that ROP18 and GRA7 act in a complex to target IRGs by distinct mechanisms that are synergistic.
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pathogenesis | innate immunity | cooperative polymerization T he apicomplexan parasite Toxoplasma gondii has a remarkable host range and is capable of infecting most warm-blooded animals (1) . The cellular life cycle of this opportunistic pathogen involves active invasion of nucleated host cells and establishment of an intracellular niche within the parasitophorous vacuole. This compartment is demarcated by the parasitophorous vacuole membrane (PVM), which avoids fusion with the host endomembrane system, although being studded with many parasite proteins (2) . PVM-localized proteins derive from two major organelles: the rhoptries (ROP proteins) and the dense granules (GRA proteins), which are sequentially secreted upon invasion (3) . The strategic location of GRAs and ROPs on the PVM positions them to play important roles in interacting with the host.
ROP proteins are secreted directly into the host cell cytosol at the time of invasion, after which they target to the PVM or other locations within the cell (4) . Although many ROP proteins contain a kinase fold, nearly half of these are predicted to be pseudokinases because they lack the critical catalytic residues that are normally required for phosphate transfer (5) . Often, these pseudokinases (i.e., ROP5, ROP8/2, ROP4/7) exist as tandem gene duplications and show evidence of positive selection (5) . Following secretion, ROP2 family members are targeted to the cytoplasmic face of the PVM via a series of amphipathic α-helical regions in their N termini (6, 7) . ROP proteins generated renewed interest when it became evident that some ROPs confer critical strain-specific virulence in mice (8) (9) (10) (11) (12) . In particular, the active kinase ROP18 and the pseudokinase ROP5 defend the parasite vacuole by blocking the function of mouse immunity-related GTPases (IRGs) (4) . Following up-regulation by IFN-γ, IRGs target susceptible parasites for destruction by relocating to the parasite vacuole and vesiculating the PVM (13) . Under normal conditions, immunityrelated GTPase family M (IRGM) proteins that are found on host endomembranes bind IRGs and maintain them in an inactive state (14) . Upon infection, IRGs are preferentially recruited to pathogen-containing vacuoles due to an absence of IRGM proteins (14) . However, virulent strains of T. gondii that express a type I allele of ROP18, an active serine/threonine kinase, are able to phosphorylate IRGs, and thus to decrease their recruitment to the PVM (15, 16) . The activity of ROP18 is regulated by a related pseudokinase ROP5 (17) , which also binds to monomeric Irga6 and blocks its assembly in vitro (18, 19) . Recent evidence implicates ROP5 and ROP18 in avoidance of guanylate binding proteins, which also contribute to restriction of T. gondii in IFN-γ-activated macrophages (20) .
Kinases often interact with pseudokinases and scaffolding proteins for regulation or substrate recruitment (21, 22) . Consequently, we were interested in whether ROP18 forms a complex with other parasite proteins that might influence its activity or function. Our studies establish that ROP18 is part of a complex with the related pseudokinases ROP8/2 and the dense granule protein GRA7, the latter of which acts synergistically with ROP18 in controlling acute virulence in the mouse.
Results
Characterization of ROP18-Containing Complexes. To identify ROP18 interacting partners, we immunoprecipitated ROP18 from cells infected with a transgenic type III strain parasite expressing active ROP18 (i.e., CTG + ROP18-Ty) vs. CTG, which lacks ROP18 expression (9) . Tandem MS (MS/MS) analysis revealed that ROP18
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(detected by 26 unique peptides) was specifically associated with the rhoptry pseudokinase ROP2 (detected by 15 unique peptides) and GRA7 (detected by 11 unique peptides) (Table S1 ). A majority of peptides matched ROP2, whereas four peptides also matched ROP8, a closely related protein that is located immediately upstream in the same locus, referred to here as ROP8/2 (Fig. S1 ). Two peptides of ROP4/7 were also identified in the ROP18-Ty immunoprecipitation (IP), which may reflect the previously described interaction between GRA7 and ROP4/7 (23) . To validate the ROP18 binding partners identified by MS/MS, GRA7 was immunoprecipitated from WT RH strain vs. Δgra7 mutant parasites under similar conditions and analyzed by MS/MS. This reciprocal IP revealed an almost identical set of proteins comprising the bait protein GRA7 (14 peptides), ROP2 (14 peptides), ROP4 (8 peptides), ROP7 (5 peptides), ROP18 (4 peptides), and ROP5 (19 peptides) (Table S2 ). These proteins were enriched in the IP samples from WT parasites but not in those from Δgra7 mutant parasites (Table S2 ). Although ROP5 was not seen in the ROP18-Ty IP, its presence in the GRA7 complex, together with ROP18, is consistent with the observation that ROP5 regulates the kinase activity of ROP18 (17) . To confirm the interaction shown by MS, we immunoprecipitated ROP18 from CTG + ROP18-Ty parasites vs. CTG parasites and performed Western blotting to detect interacting partners. ROP2 and GRA7 were specifically coprecipitated with ROP18 ( Fig. 1A) , whereas GRA5, another secretory protein that also localizes to the PVM, did not associate with ROP18 (Fig. 1A) , demonstrating the specificity of this complex.
ROP18 and GRA7 Localize to the Cytosolic Face of the PVM. The identification of GRA7 as part of a complex with ROP18 suggested that it might localize to the external surface of the PVM after secretion, similar to ROP18 (6). To determine whether GRA7 also localizes to this interface, digitonin was used to permeabilize infected host cells selectively. Under these semipermeabilized conditions, antibodies to both ROP18 and GRA7 stained the cytoplasmic surface of the PVM at both 30 min and 12 h, whereas staining of the parasite surface antigen (SAG1) remained negative (Fig. 1B, Upper) . In contrast, when Triton X-100 was used to permeabilize all membranes fully, positive staining for SAG1 was observed, as well as staining for GRA7 in dense granules and ROP18-Ty in rhoptries (Fig. 1B , Lower; both proteins are extracted from the PVM under these conditions). Combined with the MS/MS data above, these findings support the existence of a complex consisting of ROP18, GRA7, and ROP8/2 on the surface of the PVM in infected cells.
Analysis of ROP18 Complex Deletion Mutants. To explore the functions of GRA7 and ROP8/2, we made single deletions of each gene by homologous recombination (Fig. S1 and Table  S3 ). Furthermore, ROP8/2 and ROP18 were each separately deleted in the Δgra7 parasite line to create two double-deletion mutants (Fig. S2 ). Drug-resistant parasite pools were cloned by limiting dilution and screened by PCR (Figs. S1 and S2 and Table S3 ) and Western blotting (Fig. 1C) for their respective gene deletions. The Δgra7Δrop18 parasites were then complemented with either GRA7 or ROP18-Ty, and single-cell clones were confirmed for proper protein expression and localization (Fig. S3) .
GRA7 was previously implicated in nutrient acquisition (24), so we were interested in whether the Δgra7 parasites would exhibit any growth defect in vitro. Plaque assays were performed on the WT parasites and various mutant parasites to test whether deletion caused a growth defect. At 7 d postinfection, the number of plaques was comparable for WT and all mutant lines ( Fig. 1D and Fig. S4A ). Relative plaque size measurements and replication assays further confirmed the absence of an in vitro growth defect of the Δgra7 mutant ( Fig. S4 B and C). We also analyzed the ultrastructure of WT and Δgra7Δrop18 parasite vacuoles by EM and observed no differences in either the presence of the tubulovesicular network (TVN) or the general architecture of the network (Fig. S5 ). In addition, we observed normal localization of both ROP18 and ROP5 on Δgra7 vacuoles ( Fig. S6 A and B) . Hence, the defects described below for the Δgra7Δrop18 parasites are not related to adverse effects on growth or differences in vacuole morphology or composition. Combined Deletion of ROP18 and GRA7 Leads to Severe Attenuation of Acute Virulence. Because RO18 plays an important role in the virulence of T. gondii in mice (15-17), we were interested in whether the ROP8/2 and GRA7 proteins might also contribute to this phenotype. When challenged with Δrop8/2 parasites, outbred CD-1 mice died with almost identical kinetics to WT parasites ( Fig. 2A) . In comparison, CD-1 mice infected with Δgra7 and Δgra7Δrop8/2 parasites experienced a slight delay in time to death that was not as severe as that seen with Δrop18 parasites (Fig. 2A) . In contrast, all CD-1 mice challenged with the Δgra7Δrop18 parasites survived (Fig. 2A) . To establish the extent of this attenuation, we examined the dose-dependent mortality of mice following challenge with Δgra7Δrop18 parasites. Although a dose of 10 3 parasites led to survival of CD-1 mice, higher doses resulted in a dose-dependent mortality (Fig. 2B) . Complementation of the Δgra7Δrop18 parasites with either GRA7 (Δrop18/GRA7) or ROP18-Ty (Δgra7/ROP18-Ty) restored virulence to the approximate levels of the single mutants (Fig. 2C) .
To determine the importance of immunity in the attenuation of the double mutant, we injected the Δgra7Δrop18 parasites into IFN-γ receptor (IFN-γR) −/− mice, which are highly susceptible to Δrop18 and Δrop5 mutants of T. gondii (17) . Mutant Δgra7Δrop18 parasites killed IFN-γR −/− mice within 10 d postinfection but remained avirulent in control C57BL/6 mice (Fig. 2D ). This finding indicates that the attenuation of Δgra7Δrop18 parasites is a consequence of immunological control and not due to intrinsic differences in growth.
Δgra7Δrop18 Parasites Show Increased IRG Recruitment and Are
Cleared by Activated Macrophages. The observation that the attenuation of Δgra7Δrop18 parasites relies on IFN-γ signaling suggested that the double mutant may be more susceptible to the IRG pathway, which is a known target of ROP18 (15, 16) . Consistent with this, we observed a significant increase in the extent of Irga6 (Fig. 3 A and B) and Irgb6 ( Fig. 3 C and D) localization to Δgra7Δrop18 parasite vacuoles in IFN-γ-activated macrophages. When complemented with GRA7 or ROP18, levels of Irga6 and Irgb6 recruitment to the vacuole were restored to WT levels ( Fig. 3 A-D) .
Based on the increased levels of IRG recruitment, we hypothesized that the double-mutant parasites might also be cleared more effectively in IFN-γ-activated macrophages. Although Δrop18 parasites were more efficiently cleared than WT parasites at 20 h postinfection, the survival of Δgra7 mutants was unchanged (Fig. 3E ). Consistent with the higher level of IRG recruitment to vacuoles surrounding the double mutant, significantly fewer Δgra7Δrop18 parasites survived compared with the single Δrop18 mutant (Fig. 3E) . Complementation with either GRA7 or ROP18 restored the survival defect seen in the double mutant (Fig. 3E) .
The enhanced recruitment and clearance of the double mutant suggested that ROP18 and GRA7 act together to block the IRG pathway, albeit with ROP18 having a more dominant role. To test this prediction, we examined the survival of Δgra7 and Δgra7Δrop18 parasites in Irgm3 −/− mice, which are defective in loading of IRGs onto the PVM (25) . Although we observed a slight delay in time to death of outbred CD-1 mice challenged with Δgra7 mutants (Fig. 2A) , this effect was eliminated in the more susceptible C57BL/6 strain and in Irgm3 −/− mice (Fig. 3F) . Consistent with the idea that GRA7 and ROP18 act synergistically to avoid IRG-mediated killing, the normally attenuated Δgra7Δrop18 mutant killed Irgm3 −/− mice within 10 d (Fig. 3F ).
GRA7 Binds to and Stimulates Rapid Turnover of the GTP-Activated
Irga6 Oligomer in Vitro. Increased recruitment of IRGs to the vacuole surrounding Δgra7Δrop18 parasites, as well as the complete reversal of the Δgra7Δrop18 avirulence in Irgm3
mice, led us to test whether GRA7 directly affects IRG function. Irga6 oligomerization was monitored by 90°light scattering, as described previously (26) . Addition of GTP to Irga6 alone caused an increase in light scattering consistent with polymerization ( Fig.  4A) . Addition of substochiometric amounts of GRA7 resulted in an increase in light scattering (Fig. 4A) , suggesting it promotes oligomerization and/or cross-links and bundles Irga6. Sedimentation assays revealed more Irga6 in the pellet fraction at the peak of light scattering when GRA7 was present compared with Irga6 alone (Fig. S7A) . The subsequent decrease in light scattering, which corresponds to depolymerization (26), occurred much faster and dropped to a much lower level in the presence of GRA7 (Fig.  4A and Fig. S7A ). Altered kinetics of polymerization and turnover of Irga6 showed a dose-dependent response with addition of GRA7 (Fig. 4B) .
To determine the mechanism of this disruption, we examined the interaction of His 6 -tagged GRA7 with recombinant Irga6. GRA7 coprecipitated recombinant Irga6 in the presence of GTP but not GDP (Fig. 4C) , suggesting that it recognizes GTP-bound dimers and/or oligomers but not GDP-bound monomers of Irga6 (26, 27) . Precipitation was not due to formation of large oligomers or aggregates of Irga6 and GRA7, as shown by the failure of these proteins to pellet in the absence of Ni beads (Fig. S7B) . The interaction between GRA7 and Irga6 was also not the result of nonspecific binding to Ni beads, because an untagged version of GRA7 did not bring down Irga6 in the presence of beads; however, it was still able to alter the polymerization of Irga6 (Fig. S7B) . Moreover, His 6 -tagged aldolase, an unrelated glycolytic enzyme, did not precipitate Irga6 (Fig. 4C) . In addition, a GRA7 mutant (GRA7 MUT) that was modified to eliminate the hydrophobic transmembrane domain (Fig. S7C) was also able to precipitate Irga6 efficiently (Fig. 4C) , suggesting that the interaction does not depend on the putative transmembrane domain of GRA7. To test the specificity of the GRA7-Irga6 interaction further, we took advantage of previous studies that have defined the importance of GTP hydrolysis on the formation of Irga6 oligomers. Irga6 binds to 2′dGTP and 3′ dGTP but only oligomerizes with 2′dGTP (27) . GRA7 bound to Irga6 in the presence of 2′dGTP but not 3′dGTP (Fig. 4D) , indicating that GRA7 binds to oligomers of Irga6. In addition, two Irga6 point mutants, T102A and T108A, which are incapable of hydrolyzing GTP or oligomerizing (16) , were also unable to bind to GRA7 (Fig. 4D) . In accordance with the increase in light scattering of Irga6 in the presence of GRA7, addition of GRA7 stimulated higher phosphate release from the GTPase activity by Irga6 compared with Irga6 alone (Fig. 4E) . WT and deletion mutants were injected into CD-1 mice (100 parasites, s.c. inoculation), and survival was followed for 30 d (n = 10 mice for all strains except Δrop8/2 and Δgra7Δrop8/2, where n = 5 mice). ****P < 0.0001, Gehan-Breslow Wilcoxon test. (B) Dose-dependent mortality of Δgra7Δrop18 parasites. CD-1 mice (n = 5) were injected i.p with varying doses of parasites, and survival was followed for 30 d. (C) Δgra7Δrop18 parasites and their singly complemented strains (i.e., Δrop18/GRA7, Δgra7/ROP18-Ty) were injected into C57BL/6 mice (100 parasites, s.c. inoculation), and survival was monitored for 30 d (n = 10 mice for all strains). ****P < 0.0001, GehanBreslow Wilcoxon test. (D) Survival of WT C57BL/6 mice vs. IFN-γR −/− mice challenged with Δgra7Δrop18 parasites. Mice (n = 10) were injected i.p. with 100 Δgra7Δrop18 parasites, and survival was followed for 30 d.
Discussion
Our findings reveal that ROP18 exists in a protein complex on the PVM with the parasite pseudokinases ROP8/2 and GRA7. Previous co-IPs also identified an interaction between the pseudokinases ROP4/7, ROP8/2, and GRA7 and demonstrated that these proteins become phosphorylated within the host cell (23) . Deletion of either GRA7 or ROP8/2 alone did not decrease virulence, unlike the loss of ROP18, suggesting that GRA7 and ROP8/2 are not involved in regulating ROP18 function. However, the combined loss of ROP18 and GRA7 led to a much greater attenuation than the loss of either gene alone. DoubleΔgra7Δrop18 mutants showed increased recruitment of IRGs and clearance in IFN-γ-activated macrophages. The avirulence phenotype of this double mutant was reverted in Irgm3 −/− mice, implicating the complex in avoidance of the IRG pathway. GRA7 bound to Irga6-GTP in vitro, enhancing the initial rate of polymerization but eventually leading to a rapid disruption of the oligomeric complex. These findings suggest a unique role for GRA7 in combating cell-autonomous defenses by altering IRG polymerization kinetics.
Despite a previously suggested role of GRA7 in nutrient acquisition (24), we did not observe any defect in growth of the Δgra7 mutant under conditions examined here. Moreover, the Δgra7 mutant showed a normal PVM and TVN structure and normal distribution of the virulence factors ROP18 and ROP5 on the PVM. Loss of GRA7 did not directly affect IRG loading or clearance in IFN-γ-activated macrophages, unlike deletion of GRA2, which leads to alterations in the TVN and increased IRG recruitment (18) . Deletion of GRA7 did lead to a slight delay in time to death in CD-1 outbred mice, although not in more susceptible C57BL/6 mice, suggesting there is no intrinsic growth defect of the Δgra7 mutant. Although loss of GRA7 alone had a minimal effect on survival, when combined with deletion of ROP18, it led to enhanced IRG recruitment and clearance in IFN-γ-activated macrophages in vitro and a profound loss of virulence in both CD-1 and C57BL/6 mice. The dramatic change in virulence is unlikely to be due to defects in growth in vivo, because the double-Δgra7Δrop18 mutant showed normal growth in vitro. Importantly, the decreased virulence of the Δgra7Δrop18 mutant was reversed in IFN-γR −/− mice, leading to a similar time to death as that observed previously with WT parasites (17) . The decreased virulence of the Δgra7Δrop18 mutant was also reversed in Irgm3 −/− mice, implicating IRGs in this control mechanism. The IRG proteins form the major IFN-γ-dependent resistance mechanism to T. gondii in the mouse (13) . Collectively, these findings indicate that GRA7 and ROP18 act synergistically to block the IRGs and that in the absence of this host defense pathway, they are no longer required.
GRA7 dramatically increased polymerization of Irga6 in vitro, as revealed by 90°light scattering and sedimentation. The accelerated rate of Irga6 assembly suggests that GRA7 may act as a nucleation or stabilizing factor for polymer formation. Alternatively, GRA7 may bind to small oligomers of Irga6 and cross-link or bundle them, leading to greater light scattering and sedimentation. Intriguingly, GRA7 only bound to forms of Irga6 that were competent for oligomerization. Structural and modeling studies have defined a dimer interface in Irga6 that is necessary for homo-oligomerization and mediates binding to heterodimer formation with IRGM proteins that negatively regulate polymer assembly (27) . GRA7 was unable to bind to mutants (T102 and T108) that fail to hydrolyze GTP, and hence do not undergo oligomerization (16) . Similarly, GRA7 was only able to bind to Irga6 in the presence of 2′dGTP, which induces polymerization more slowly than GTP, whereas it did not bind to Irga6 in the presence of 3′dGTP, which fails to drive oligomerization (27) .
These results suggest that GRA7 may recognize the active dimer that leads to IRG assembly, thereby taking advantage of a natural regulatory feature to alter polymerization kinetics. The function of GRA7 contrasts with that of known mediators of IRG function or GTPase effectors. IRGs exist as monomers when bound to GDP, and they oligomerize in the presence of GTP to undergo hydrolysis by a cooperative mechanism (26) . IRGs have intrinsic GTPase activating protein (GAP) activity and exchange nucleotides readily; as such, they do not rely on GAPs or guanine nucleotide exchange factors (GEFs) to regulate their functions (26) . Instead, IRGM proteins are thought to regulate IRGs by preventing their assembly through guanylate dissociation inhibitor activity that maintains them in a GDPbound state (28, 29) . Because GRA7 binds only to oligomers of Irga6-GTP and not to Irga6-GDP monomers, it is unlikely to act as a GEF. Binding of GRA7 to Irga6 oligomers slightly enhanced GTP hydrolysis and phosphate release, consistent with the increased amount of polymer formed. In addition, GRA7 greatly increased the rate of depolymerization of Irga6, resulting in faster turnover. The precise interactions between GRA7 and Irga6 that drive increased assembly and faster turnover remain to be defined by future studies.
The in vivo significance of enhanced Irga6 polymerization in the presence of GRA7 is presently unclear, although several models can be considered based on our in vitro findings. If GRA7 on the PVM were recognized by the host as a target for IRGs, we would expect to see higher recruitment to vacuoles surrounding WT parasites. This model can be ruled out because there was little change in IRG recruitment in the Δgra7 mutant, whereas the Δgra7Δrop18 mutant showed much greater recruitment of Irga6 and Irgb6. Instead, it seems likely that GRA7 disrupts IRG function by altering the kinetics of polymerization, which might occur in several different ways. First, binding of GRA7 to small oligomers or dimers may prevent them from assembling correctly on the PVM. Second, GRA7 binding to IRGs may lead to enhanced assembly but then drive rapid disassembly into inactive GDP-bound monomers. Such activity by GRA7 would be expected to make substrates available to ROP18, which phosphorylates residues in switch region I (SWI) (15, 16) , or to ROP5, which is thought to bind to monomeric IRGs to prevent their assembly (19) . Further studies are needed to define how these various virulence factors work cooperatively in vitro and in vivo to thwart the IRG system and protect the parasite from destruction.
IRGs target a variety of intracellular pathogens, including T. gondii, where they oligomerize onto the PVM and result in its vesiculation and destruction (13) . The virulence factor ROP18 phosphorylates key residues in SWI of IRGs, and this is associated with preventing their accumulation on the PVM (15, 16) . The function of ROP18 is augmented by the pseudokinase ROP5, which can directly bind to IRGs and prevent assembly in vitro (18, 19) , while also enhancing the activity of ROP18 (17) . Our findings suggest that GRA7 acts in vitro to disrupt IRGs by a unique biochemical mechanism of increasing the turnover of Irga6 oligomers, thus potentially complementing the functions of other known virulence determinants ROP18 and ROP5. This example reveals multiple layers of defense used by the parasite to counteract innate immunity in the host.
Materials and Methods
Parasite Propagation. Parasite strains (referred to in detail in Table S3 ) were passaged as tachyzoites in human foreskin fibroblast (HFF) monolayers in DMEM containing 10 mM Hepes, 10 μg/mL gentamicin, 6 mM L-glutamine, 1 mM pyruvate, and 10% (vol/vol) FBS, cultured at 37°C in 5% (vol/vol) CO 2 . Plaque assays were carried out on confluent monolayers of HFF cells as described in SI Materials and Methods.
Antibodies and Microscopy. Rabbit antisera that were specific to recombinant GRA7 or ROP2 were generated as described in SI Materials and Methods. Immunoprecipitation and Western blotting assays were performed as described previously (15) (SI Materials and Methods). Immunofluorescence microscopy to localize parasite proteins in infected cells and EM to evaluate the morphology of infected cells were performed as described previously Fig. 4 . Interaction of GRA7 and Irga6 in vitro. (A) Oligomerization of 50 μM Irg6 ± 20 μM GRA7 in a 90°light scattering assay, in which 1 mM GTP was added at the location indicated by the arrow at 37°C. AU, arbitrary units; PK, proteinase K-treated GRA7. (B) Oligomerization of 50 μM Irg6 ± GRA7 in a 90°light scattering assay in which 1 mM GTP was added at the location indicated by the arrow at 37°C. (C) GTP-dependent binding of WT (GRA7) vs. double-point mutant (GRA7 MUT) to Irga6. Supernatants (S; 10%) and pellets (P; 50%) were resolved by SDS/PAGE and stained with SYPRO Ruby. Histagged ALD (His-Ald) was included as a negative control. (D) Nucleotidedependent binding of GRA7 to Irga6. Recombinant His-tagged GRA7 (His-GRA7) was incubated with WT or mutant Irga6 and various nucleotides for 10 min at 37°C and then immunoprecipitated with Ni beads. The supernatants were resolved by SDS/PAGE and stained with SYPRO Ruby. (E) Phosphate release during oligomerization of Irga6 (50 μM); incubation ± 20 μM GRA7, 20 μM ALD (Ald), or PK-treated GRA7 (+PK); and addition of final 1 mM GTP (+GTP).
[Pi], cumulative phosphate released (micromolar) (n = 3). **** P < 0.0001, two-way ANOVA test.
(15) (SI Materials and Methods). Immunofluorescence microscopy to evaluate the recruitment of Irga6 and Irgb6 to parasite-containing vacuoles and the clearance of parasites in IFN-γ-activated RAW cells was performed as described previously (15) (SI Materials and Methods).
MS. Proteins were eluted from protein G Sepharose beads by incubation in 2% RapiGest SF surfactant (Waters) with 20 mM DTT at 95°C for 10 min, followed by 5 min at room temperature. Eluates were collected by centrifugation at 1,000 × g and digested with 2 μg of trypsin for 16 h at 37°C. Digested samples were dried and resuspended in 10 mL of 5% (vol/vol) acetonitrile in 0.1% formic acid and analyzed by liquid chromatography MS/ MS using the LTQ-Orbitrap Velos (Thermo Scientific) with a 2-h gradient. The m/z spectra data were searched using MASCOT (Matrix Science) against the GenBank nr (nonredundant) and ToxoDB 8.1 databases.
Generation of Plasmids and Transgenic Parasites. Primers used for generation of plasmids for KO or complemented strains used in this study are available on request. To generate the KO and complemented lines, plasmids were linearized and transfected into the WT parasites, and single-cell clones were isolated (Table S3) Irga6 Oligomerization Assays. Recombinant Irgs6 was expressed as GST-fusion protein, cleaved, and purified as described in SI Materials and Methods. Oligomerization of Irga6 was monitored by 90°light scattering in a total reaction volume of 150 μL containing 40 mM Tris·Cl (pH 8.0), 5 mM MgCl2, and 2 mM DTT (buffer B). Polymerization of 50 μM Irga6 alone was compared with that of Irga6 combined with different concentrations of GRA7 or proteinase K-treated GRA7 (SI Materials and Methods). Proteinase K-treated buffer A [40 mM Tris·Cl (pH 8.0), 15 mM NaCl] was added to the Irga6-only reaction as a control. The protein solutions were first equilibrated to 37°C, followed by the addition of GTP (final concentration of 1 mM), and monitored over time with a PTI Quantmaster spectrofluorometer (Photon Technology International). Curves were processed using Prism (GraphPad).
In Vitro Binding Assay. Recombinant GRA7 and T. gondii aldolase (ALD) were expressed in Escherichia coli and purified as described in SI Materials and Methods. Ni beads (Sigma-Aldrich) were either charged with His-tagged GRA7 or His-tagged ALD or left uncharged in buffer A. Irga6 (50 μM) was added to the Ni beads in a final volume of 50 μL of buffer B and various nucleotides (final concentration of 1 mM) and incubated at 37°C for 10 min. Beads were washed in buffer B, and 10% (vol/vol) of the unbound supernatant fraction and 50% (vol/vol) of the bound-bead fraction were resolved on 10% (vol/vol) acyrlamide gels by SDS/PAGE and stained with SYPRO Ruby (Invitrogen).
GTP Hydrolysis Assays. To measure phosphate release, 50 μM purified Irga6 was incubated with either 20 μM GRA7, 20 μM proteinase K-treated GRA7, 20 μM ALD, or proteinase K-treated buffer A in the presence of 1 mM GTP in buffer B at 37°C. As negative controls, Irga6 and GRA7 without GTP and GRA7 alone were incubated similarly. At time intervals, reactions were sampled and phosphate release was measured using a GTPase colorimetric kit (Innova Biosciences). Pi release from incubation of GTP alone was subtracted from the samples containing GTP.
Statistics. Student t tests were performed under the assumption of equal variance and with a two-tailed test, where P ≤ 0.05 was considered significant. Graphs were plotted with mean ± SD of the population or SD as noted. Scatter plots were analyzed using the Mann-Whitney test for statistical significance under nonparametric conditions not assuming Gaussian distribution and a two-tailed test, where P ≤ 0.05 was considered significant. Kaplan-Meier plots that were analyzed using the Gehan-Breslow Wilcoxon test, where P ≤ 0.05 was considered significant. For the phosphate release assay, curves were analyzed by a two-way ANOVA test, where P ≤ 0.05.
